Clinical Trials in Goslar, Germany
6 recruiting
Showing 1–9 of 9 trials
Recruiting
Phase 3
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
Heart Failure and Impaired Kidney Function
AstraZeneca4,800 enrolled842 locationsNCT06307652
Recruiting
Phase 3
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
Cardiovascular DiseasesHypertensionDiabetes Mellitus, Type 2
Boehringer Ingelheim11,800 enrolled1153 locationsNCT07064473
Recruiting
A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer at High Risk of Recurrence
Breast Neoplasms
Novartis Pharmaceuticals3,250 enrolled267 locationsNCT06830720
Recruiting
NIS to Examine the Effectiveness and Safety of Durvalumab and Olaparib in Patients With Endometrial Cancer (DUOLife)
Endometrial Cancer
AstraZeneca150 enrolled33 locationsNCT06890273
Recruiting
NIS to Examine the Effectiveness of TDC in Patients With Metastatic Non-squamous NSCLC and High-risk Genetic Alterations
Non-squamous Metastatic Non-Small-Cell Lung Carcinoma
AstraZeneca600 enrolled21 locationsNCT06494540
Recruiting
Study of the Use of Venetoclax in Participants With Chronic Lymphocytic Leukemia (CLL) Under Real-Life Setting
Chronic Lymphocytic Leukemia (CLL)
AbbVie500 enrolled70 locationsNCT03342144
Recruiting
Phase 2
Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer
Advanced or Metastatic Breast CancerBRCA1 MutationBRCA2 Mutation+1 more
GBG Forschungs GmbH176 enrolled36 locationsNCT06201234
Recruiting
BRAF Inhibitor Encorafenib And Cetuximab Real Life Investigation of Next Generation CRC Treatment
Metastatic Colorectal Carcinoma
Pierre Fabre Pharma GmbH500 enrolled70 locationsNCT04673955
Recruiting
Binimetinib Plus Encorafenib Real Life Investigation of Next Generation Melanoma Treatment
Melanoma Stage IVMelanoma Stage III
Pierre Fabre Pharma GmbH750 enrolled59 locationsNCT04045691